Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injection
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SWITCH-1
- 02 Oct 2017 Status changed from recruiting to discontinued.
- 18 Sep 2012 Planned End Date changed from 1 Mar 2013 to 1 May 2013 as reported by University Hospital Medical Information Network - Japan.
- 10 May 2012 New trial record